IN2012DN02345A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN02345A IN2012DN02345A IN2345DEN2012A IN2012DN02345A IN 2012DN02345 A IN2012DN02345 A IN 2012DN02345A IN 2345DEN2012 A IN2345DEN2012 A IN 2345DEN2012A IN 2012DN02345 A IN2012DN02345 A IN 2012DN02345A
- Authority
- IN
- India
- Prior art keywords
- nucleic acid
- stranded
- methods
- tlrs
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Abstract
The present invention relates, in general, to pattern-recognition receptors (PRRs), including toll-like receptors (TLRs), and, in particular, to a method of inhibiting nucleic acid-induced activation of, for example, endosomal TLRs using an agent that binds to the nucleic acid ("nucleic acid binding agent"), preferably, in a manner that is independent of the nucleotide sequence, the chemistry (e.g., DNA or RNA, with or without base or sugar modifications) and/or the structure (e.g., double-stranded or single-stranded, complexed or uncomplexed with, for example protein) of the nucleic acid(s) responsible for inducing TLR activation. The invention also relates to methods of identifying nucleic acid binding agents suitable for use in such methods.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24309009P | 2009-09-16 | 2009-09-16 | |
PCT/US2010/002516 WO2011034583A2 (en) | 2009-09-16 | 2010-09-16 | Inhibition of endosomal toll-like receptor activation |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012DN02345A true IN2012DN02345A (en) | 2015-08-21 |
Family
ID=43759220
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN2345DEN2012 IN2012DN02345A (en) | 2009-09-16 | 2010-09-16 |
Country Status (6)
Country | Link |
---|---|
US (3) | US9468650B2 (en) |
EP (1) | EP2477641B1 (en) |
CN (1) | CN102639142A (en) |
CA (1) | CA2774460C (en) |
IN (1) | IN2012DN02345A (en) |
WO (1) | WO2011034583A2 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101702917A (en) | 2007-03-30 | 2010-05-05 | 杜克大学 | A method of modulating the activity of a nucleic acid molecule |
EP2477641B1 (en) | 2009-09-16 | 2024-03-27 | Duke University | Inhibition of endosomal toll-like receptor activation for treating thrombotic disorders |
WO2012151575A2 (en) | 2011-05-05 | 2012-11-08 | Duke University | A method of controlling coagulation |
WO2014169043A1 (en) * | 2013-04-09 | 2014-10-16 | Duke University | Anti-inflammatory agents and methods of using the same |
US10066323B2 (en) | 2014-04-16 | 2018-09-04 | Duke University | Electrospun cationic nanofibers and methods of making and using the same |
EP3512526A4 (en) | 2016-09-16 | 2020-05-27 | Duke University | Von willebrand factor (vwf)-targeting agents and methods of using the same |
JP7231229B2 (en) | 2017-03-23 | 2023-03-01 | デューク ユニバーシティ | Antidote-mediated release of extracellular aptamer staining |
WO2018222484A1 (en) * | 2017-05-30 | 2018-12-06 | The Trustees Of Columbia University In The City Of New York | Cationic nucleic acid scavenger and uses thereof |
WO2021016924A1 (en) * | 2019-07-31 | 2021-02-04 | 中山大学 | Cationic polymer and particles usable to treat psoriasis |
EP4249913A1 (en) * | 2022-03-22 | 2023-09-27 | Centre Hospitalier Universitaire de Nîmes | Toll-like-receptor 3 inhibitor for preventing and/or treating disorders in patients with a personal history of venous thromboembolism (vte) |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5919761A (en) | 1992-08-14 | 1999-07-06 | The Board Of Regents Of The University Of Michigan | Peptides for heparin and low molecular weight heparin anticoagulation reversal |
US6037329A (en) | 1994-03-15 | 2000-03-14 | Selective Genetics, Inc. | Compositions containing nucleic acids and ligands for therapeutic treatment |
US6624141B1 (en) | 1999-03-17 | 2003-09-23 | The Regents Of The University Of Michigan | Protamine fragment compositions and methods of use |
EP1343371A4 (en) | 2000-09-08 | 2004-08-04 | Invitrogen Corp | Compositions and methods for enhanced sensitivity and specificity of nucleic acid synthesis |
USRE43612E1 (en) | 2000-10-10 | 2012-08-28 | Massachusetts Institute Of Technology | Biodegradable poly(β-amino esters) and uses thereof |
EP1347776A2 (en) | 2001-01-05 | 2003-10-01 | Intercell Biomedizinische Forschungs- und Entwicklungs AG | Anti-inflammatory use of polycationic compounds |
KR20030082961A (en) | 2001-03-08 | 2003-10-23 | 메르크 파텐트 게엠베하 | Modified protamine with reduced immunogenicity |
AU2002312059B2 (en) | 2001-05-25 | 2009-01-15 | Duke University | Modulators of pharmacological agents |
AUPR604101A0 (en) | 2001-06-29 | 2001-07-26 | Unisearch Limited | Aptamers |
US20050136040A1 (en) | 2001-10-11 | 2005-06-23 | Imperial College Innovations Limited | Control of gene expression using a complex of an oligonucleotide and a regulatory peptide |
IL161733A0 (en) | 2001-11-02 | 2005-11-20 | Insert Therapeutics Inc | Methods and compositions for therapeutic use of rna interference |
US20040063654A1 (en) | 2001-11-02 | 2004-04-01 | Davis Mark E. | Methods and compositions for therapeutic use of RNA interference |
US20030180250A1 (en) * | 2002-03-22 | 2003-09-25 | Council Of Scientific And Industrial Research | Compositions and complexes containing a macromolecular compound as potential anti-inflammatory agents |
EP1549269A4 (en) | 2002-10-09 | 2010-10-06 | Cerulean Pharma Inc | Cyclodextrin-based materials, compositions and uses related thereto |
US20050136430A1 (en) | 2003-07-15 | 2005-06-23 | California Institute Of Technology | Inhibitor nucleic acids |
US20050256071A1 (en) | 2003-07-15 | 2005-11-17 | California Institute Of Technology | Inhibitor nucleic acids |
AU2005238490B2 (en) | 2004-04-22 | 2010-11-18 | Tobira Therapeutics, Inc. | Improved modulators of coagulation factors |
US8080245B2 (en) | 2004-08-04 | 2011-12-20 | University Of Massachusetts | Anti-pathogen immunoadhesins |
GB0422877D0 (en) * | 2004-10-14 | 2004-11-17 | Univ Glasgow | Bioactive polymers |
ES2381201T3 (en) | 2005-03-31 | 2012-05-24 | Calando Pharmaceuticals, Inc. | Inhibitors of the subunit 2 of the ribonucleotide reductase and uses thereof |
US7611835B2 (en) | 2005-09-30 | 2009-11-03 | Battelle Memorial Institute | Process for preparing multilayer enzyme coating on a fiber |
WO2007070682A2 (en) | 2005-12-15 | 2007-06-21 | Massachusetts Institute Of Technology | System for screening particles |
WO2007140000A2 (en) | 2006-05-26 | 2007-12-06 | Regado Biosciences, Inc. | Administration of the reg1 anticoagulation system |
US8470963B2 (en) * | 2006-06-30 | 2013-06-25 | Sku Asset Management Gmbh | Multifunctional compounds for pharmaceutical purposes |
US20110118187A1 (en) | 2006-10-19 | 2011-05-19 | Duke University | Reversible platelet inhibition |
US20100028402A1 (en) | 2006-10-25 | 2010-02-04 | Marina Dobrovolskaia | Nanoparticle-based anticoagulant |
JP5755839B2 (en) | 2007-02-15 | 2015-07-29 | マンカインド コーポレイション | Method for enhancing T cell response |
CN101702917A (en) | 2007-03-30 | 2010-05-05 | 杜克大学 | A method of modulating the activity of a nucleic acid molecule |
CN101808730A (en) | 2007-09-27 | 2010-08-18 | Sca卫生用品公司 | Claylinked polymer gels |
US20100285081A1 (en) | 2007-11-12 | 2010-11-11 | Massachusetts Institute Of Technology | Bactericidal Nanofibers, and Methods of Use Thereof |
WO2010020008A1 (en) | 2008-08-22 | 2010-02-25 | Polymers Crc Limited | Polymer coatings |
WO2010132879A2 (en) | 2009-05-15 | 2010-11-18 | The Johns Hopkins University | Multicomponent degradable cationic polymers |
EP2477641B1 (en) | 2009-09-16 | 2024-03-27 | Duke University | Inhibition of endosomal toll-like receptor activation for treating thrombotic disorders |
US20130266664A1 (en) | 2010-12-20 | 2013-10-10 | Virginia Commonwealth University | Facile method for crosslinking and incorporating bioactive molecules into electrospun fiber scaffolds |
WO2013040552A2 (en) | 2011-09-16 | 2013-03-21 | Georgia Health Sciences University | Methods of promoting immune tolerance |
-
2010
- 2010-09-16 EP EP10817556.3A patent/EP2477641B1/en active Active
- 2010-09-16 CA CA2774460A patent/CA2774460C/en active Active
- 2010-09-16 US US13/496,313 patent/US9468650B2/en active Active
- 2010-09-16 CN CN2010800511149A patent/CN102639142A/en active Pending
- 2010-09-16 WO PCT/US2010/002516 patent/WO2011034583A2/en active Application Filing
- 2010-09-16 IN IN2345DEN2012 patent/IN2012DN02345A/en unknown
-
2016
- 2016-10-12 US US15/291,849 patent/US11617779B2/en active Active
-
2023
- 2023-03-30 US US18/128,957 patent/US20230248805A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20230248805A1 (en) | 2023-08-10 |
WO2011034583A3 (en) | 2011-10-06 |
US20170095503A1 (en) | 2017-04-06 |
US11617779B2 (en) | 2023-04-04 |
CA2774460A1 (en) | 2011-03-24 |
CN102639142A (en) | 2012-08-15 |
US9468650B2 (en) | 2016-10-18 |
EP2477641B1 (en) | 2024-03-27 |
EP2477641A2 (en) | 2012-07-25 |
EP2477641A4 (en) | 2013-08-07 |
US20120183564A1 (en) | 2012-07-19 |
WO2011034583A2 (en) | 2011-03-24 |
CA2774460C (en) | 2016-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2012DN02345A (en) | ||
BR112014005205A2 (en) | methods for tagging dna encoded libraries | |
WO2007136736A3 (en) | Methods for nucleic acid sorting and synthesis | |
MX2010002113A (en) | Methods for detecting oligonucleotides. | |
WO2007127219A3 (en) | Targeted delivery to leukocytes using protein carriers | |
HK1116836A1 (en) | Multicomponent nucleic acid enzymes and methods for their use | |
MX2015005328A (en) | Compositions and methods for selective delivery of oligonucleotide molecules to cell types. | |
WO2010026488A3 (en) | Methods and kits for nucleic acid sequencing | |
WO2011079902A3 (en) | Biological inhibitors of ror1 capable of inducing cell death | |
WO2008063203A3 (en) | Compositions and methods for efficient gene silencing in plants | |
WO2008061537A3 (en) | Oligonucleotides for modulating target rna activity | |
SG170802A1 (en) | Systems and devices for sequence by synthesis analysis | |
WO2005097993A3 (en) | Immunostimulatory viral rna oligonucleotides | |
WO2010141511A3 (en) | Polynucleotides for multivalent rna interference, compositions and methods of use thereof | |
WO2008151631A3 (en) | Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis | |
WO2006019430A3 (en) | Methods and compositions for enhancing delivery of double-stranded rna or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells | |
EP2647711A3 (en) | Alternative export pathways for vector expressed RNA interference | |
WO2006012468A3 (en) | Detection of oligonuleotides by dual hybridization | |
MX2007004686A (en) | Multidomain rna molecules comprising at least one aptamer for delivering double stranded rna to pest organisms. | |
ATE534737T1 (en) | TARGETED DELIVERY OF SIRNA | |
AR067135A1 (en) | METHODS TO ISOLATE LONG FRAGMENT RNA FROM FIXED SAMPLES | |
MXPA02000819A (en) | Tenascin c nucleic acid ligands. | |
AU2014219019A8 (en) | Short interfering nucleic acid (siNA) molecules containing a 2' internucleoside linkage | |
WO2011056073A3 (en) | Novel compounds for modulating neovascularisation and methods of treatment using these compounds | |
WO2009012363A3 (en) | Nucleotides and aptamers containing boronic acid groups having biased binding to glycosylated proteins, and uses thereof |